Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $476.95, signifying a +1.45% move from its prior day's close.

Vertex Pharmaceuticals (VRTX) received a significant boost as Health Canada's approval of ALYFTREK marked a vital step in expanding cystic fibrosis treatment options. This approval and other successes ...

Vertex Pharmaceuticals, under the leadership of CEO Reshma Kewalramani, was named in the “Impact Awards” category, which spotlights five standout companies making meaningful advancements in their ...

Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo & Co. (WFC), Abbott Laboratories (ABT) and American Express Co. (AXP), as well as two micro-cap stocks ...

Discover the top 10 large-cap stocks rated Buy across Seeking Alpha, Wall Street, and analyst systems, featuring strong ...

Indian American entrepreneur among six esteemed alumni recognized for demonstrating exceptional leadership in their ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals received a boost with Canada's approval of ALYFTREK for cystic fibrosis. This approval boosts sentiment. The stock saw a 7% rise over the past month amid broader market optimism ...

A major lab project nearing completion in the Seaport District is providing seed money to memorialize what was once a major ...

Proteus Syndrome Market Insight, Epidemiology and Market Forecast - 2034The Proteus Syndrome market is entering a pivotal decade, driven by ...

Following an unprecedented AI chip demand, NVIDIA recently became the first company to reach a market capitalization of $4 ...

Private Advisor Group has upped its investment in Regeneron Pharmaceuticals, acquiring an additional 1,957 shares. The move ...